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In their review, Spronk and colleagues [1] address some of
the very real dilemmas faced by clinicians during the
resuscitation of critically ill patients with trauma or sepsis.
Having made a diagnostic judgment as to the presenting
problem – sepsis or trauma – the clinician must next decide
on the phase of resuscitation that the patient is in – ‘flow’
phase versus ‘ebb’ phase [2]. Finally, the clinician must
determine what therapeutic strategies to employ and judge
when resuscitation is complete. In this commentary I take the
clinician’s perspective in attempting to translate what we
have learned from many years of preclinical study.
Additionally, I identify areas where evidence remains elusive,
and therefore where the clinician’s judgment, incorporating
‘the art of medicine’, must dominate the treatment plan.
The clinician must first determine whether they are dealing
simply with the resuscitation of a traumatized patient in
whom, in the absence of direct cardiac injury, the prevailing
pathophysiologic disease mechanism is intravascular volume
loss. Alternatively, are they dealing with the more complex
problem of a patient with the sepsis/systemic inflammatory
response syndrome (SIRS) continuum, in which
dysregulation of tissue oxygen delivery occurs because of
abnormalities at all three levels of the circulation: the cardiac
output, the distribution of blood flow, and blood flow
distribution within organs [3]. In the former situation,
resuscitation must include early diagnostic strategies that
identify the cause of intravascular volume loss. For the latter,
resuscitation must include strategies that identify whether the
patient is infected (is it sepsis or SIRS?), and if the patient is
infected then where. Debating the adequacy of and novel
approaches to resuscitation in either trauma or sepsis is a
moot exercise if the clinician fails to remember that source
control must occur in parallel with resuscitation.
Unfortunately, there remain examples in the clinical literature
of patients being committed to the study of novel treatment
approaches while the underlying cause of the problem
remained untreated [4].
For the critical care basic scientist, there remain elusive
issues about the underlying pathophyiology of these
diseases, especially sepsis. An understanding of the
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Abstract
Resuscitation of critically ill patients with trauma or sepsis continues to challenge clinicians. Early
imperatives include diagnostic judgment as to the presenting problem – sepsis or trauma.
Subsequently, the clinician decides on the phase of resuscitation required for support – ‘ebb’ versus
‘flow’. Finally, the clinician needs to determine what therapeutic strategies to employ and then judge
when resuscitation is complete. Shortcomings of current approaches to determining the adequacy of
circulatory resuscitation have prompted the evaluation of new technologies purported to directly
assess microcirculatory flow as a clinical endpoint for the adequacy of resuscitation. While early
studies are intriguing, this technology requires much more study before it can be considered for
widespread adoption by the clinician.
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mechanism of multiple organ dysfunction in sepsis (and in
SIRS) could be critical to determining ancillary therapeutic
approaches that could improve intensive care unit related
outcomes from this syndrome. As Spronk and coworkers
note [1], animal studies have taught us that impaired
microcirculatory perfusion is a crucial finding in many
organs in sepsis [5,6]. In addition, although a primary cause
remains unknown, Spronk and colleagues summarize many
possible reasons for reported derangements in
microcirculatory flow in sepsis, including abnormal
leukocyte–endothelial interactions, impaired deformability of
red cells, alterations in viscosity and increases in
microvascular permeability leading to tissue edema. The
presumed pathway to organ dysfunction in this scenario
would be ischemic tissue injury complicating an imbalance
between tissue oxygen needs and microvascular oxygen
delivery – so-called ‘circulatory’ hypoxia [7]. What we do
not know yet is whether therapy directed at any or all of
these problems would either improve microvascular flow or,
even if flow were to be improved, whether improved clinical
outcomes would result [8]. In fact, it was the observation
that cell injury and death could occur in septic animal
models with normal microvascular perfusion that led us to
conclude that other causes of multiple organ dysfunction in
sepsis warrant consideration [9]. Other investigators came
to the same conclusion through different lines of reasoning,
thus leading to the hypothesis that mitochondrial
dysfunction leading to cell injury could occur in sepsis,
independent of alterations and microvascular flow –
referred to as ‘cytopathic’ hypoxia [7,10].
Whether it be trauma or sepsis, ‘ebb’ phase resuscitation (in
which the goal is restoration of perfusion pressures) takes
precedence over all else, and includes the ‘ABCs’ of
resuscitation [11]. In this phase, the clinician’s tools to
achieve completeness of resuscitation of the circulation are
probably adequate, namely monitoring the arterial pressure to
ensure it is restoration to pre-injury levels (thus consistent
with ensuring core organ perfusion monitored by changes in
sensorium and urine output). The clinical challenge is
whether circulatory resuscitation is ‘adequate’ – a question
that defines what has been referred to as ‘flow’ phase
resuscitation. Here, Spronk and coworkers [1] noted the
clinician has a few diagnostic tools available including arterial
lactates, mixed venous oxygen saturation and tonometric
partial pressures of carbon dioxide – tools with reported
strengths and weaknesses. It is because of the perceived
shortcomings of current diagnostic technologies for
assessing the adequacy of ‘flow’ phase resuscitation that
Spronk and colleagues raised the intriguing possibility direct
measurement of microcirculatory flow might be a clinical end-
point for resuscitation. As an unabashed advocate of the
crucial role of microcirculation in critical illness, I am intrigued
by this possibility, but remind the reader there are a number
of questions that must be addressed in the evaluation this
new technology.
In previous work [12,13] we discussed the phases of
evaluation that new technologies need to go through before
they can be considered for routine use; this is even more
important in today’s environment. With regard to the
hypothesis that microcirculatory perfusion should be
measured as an end-point of resuscitation, we suggest that
further preclinical studies, in acceptable animal models
conducted with the same rigor as clinical trials demand, must
be carried out to determine whether measurement of
microcirculatory flow is an acceptable surrogate of cellular
oxygen availability, and whether restoration of
microcirculatory perfusion in septic animal models improves
an outcome that could be considered a surrogate of a clinical
end-point. Furthermore, these studies must establish what
quantitative measure of microvascular perfusion (e.g.
perfused vascular density, total blood flow) is adequate for
use as a resuscitation end-point. Finally, translated to the
bedside, does the application of therapies demonstrated to
improve microcirculatory flow in preclinical studies,
conducted in appropriate animal models and monitored by
changes in directly measured microcirculatory flow, lead to
improve outcomes?
Spronk and colleagues have begun an important dialogue
regarding the use of exciting new technologies with the
potential to improve the clinician’s ability to monitor adequacy
of ‘flow’ phase resuscitation. For advocates of the
introduction of new diagnostic technology to the critical care
setting, the road to widespread clinical acceptance is
challenging but needs to have a beginning. In the nonhealth
sector, this direction begins with development of a business
case and careful implementation of its various steps, with the
courage to challenge assumptions critically with focused
study. The real challenge for colleagues who wish to
introduce diagnostic technologies to the critical care setting
is to ensure that their business case is sufficiently funded for
the long trip to adoption, which we believe has been the
reason why other technologies have not reached their full
clinical potential.
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